nach oben

Current Treatment Options in Neurology

Erschienen in:

01.10.2015 | Neuromuscular Disorders (SA Rudnicki, Section Editor)

Vasculitic Neuropathies

verfasst von: Elie Naddaf, MD, P. James Bonham Dyck, MD

Erschienen in: Current Treatment Options in Neurology | Ausgabe 10/2015

Einloggen, um Zugang zu erhalten

Opinion statement

From pathological standpoint, we divide vasculitic neuropathies in two categories: nerve large arteriole vasculitides and nerve microvasculitis. It is also important to determine whether a large arteriole vasculitis has an infectious etiology as it entails different treatment approach. Treatment of non-infectious large arteriole vasculitides consists initially of induction therapy with corticosteroids. Adding an immunosuppressant, mainly cyclophosphamide, is often needed. Treatment of infectious large arteriole vasculitides needs a multidisciplinary approach to target both the underlying infection and the vasculitis. Corticosteroids are the first-line therapy for classic non-systemic vasculitic neuropathy. Stable or improving patients without biopsy evidence of active vasculitis can be either observed or treated. Currently, adding an immunosuppressant is only indicated for patients who continue to progress on corticosteroids alone or patients with a rapidly progressive course. The treatment of the radiculoplexus neuropathies such as diabetic lumbosacral radiculoplexus neuropathy, lumbosacral radiculoplexus neuropathy (in non-diabetic patients), and diabetic cervical radiculoplexus neuropathy, as well as painless diabetic motor neuropathy, is not well established yet. We treat patients, if they present early on in the disease course or if they have severe disabling symptoms, with IV methylprednisolone 1 g once a week for 12 weeks.

Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37(2):187–92.PubMedCrossRef

Saleh A, Stone JH. Classification and diagnostic criteria in systemic vasculitis. Best Pract Res Clin Rheumatol. 2005;19(2):209–21. doi:10.1016/j.berh.2004.09.001.PubMedCrossRef

Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11. doi:10.1002/art.37715.PubMedCrossRef

4.••

Gwathmey KG, Burns TM, Collins MP, Dyck PJB. Vasculitic neuropathies. Lancet Neurol. 2014;13(1):67–82. doi:10.1016/S1474-4422(13)70236-9. It is a review of vasculitic neuropathies that complements this treatment-focused article, as it details further the clinical and laboratory findings.PubMedCrossRef

Collins MP, Periquet MI, Mendell JR, Sahenk Z, Nagaraja HN, Kissel JT. Nonsystemic vasculitic neuropathy: insights from a clinical cohort. Neurology. 2003;61(5):623–30.PubMedCrossRef

Kurt S, Alsharabati M, Lu L, Claussen GC, Oh SJ. Asymptomatic vasculitic neuropathy. Muscle Nerve. 2014. doi:10.1002/mus.24494.PubMed

Vrancken AFJE, Gathier CS, Cats EA, Notermans NC, Collins MP. The additional yield of combined nerve/muscle biopsy in vasculitic neuropathy. Eur J Neurol. 2011;18(1):49–58. doi:10.1111/j.1468-1331.2010.03041.x.PubMedCrossRef

Collins MP, Periquet MI. Isolated vasculitis of the peripheral nervous system. Clin Exp Rheumatol. 26(3 Suppl 49):S118-S130.

Guillevin L, Lhote F, Gayraud M. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. a prospective study in 342 patients. Medicine (Baltimore). 1996;75(1):17–28.CrossRef

10.

Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011;90(1):19–27. doi:10.1097/MD.0b013e318205a4c6.CrossRef

11.•

Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013;65(1):270–81. doi:10.1002/art.37721. It is a large cohort describing the main characteristics and the long-term outcome of patients with EGPA.PubMedCrossRef

12.

Moosig F, Bremer JP, Hellmich B, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis. 2013;72(6):1011–7. doi:10.1136/annrheumdis-2012-201531.PubMedCrossRef

13.

Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52(9):2926–35. doi:10.1002/art.21250.PubMedCrossRef

14.

Healy B, Bibby S, Steele R, Weatherall M, Nelson H, Beasley R. Antineutrophil cytoplasmic autoantibodies and myeloperoxidase autoantibodies in clinical expression of Churg-Strauss syndrome. J Allergy Clin Immunol. 2013;131(2):571–6. doi:10.1016/j.jaci.2012.05.058. e1-e6.PubMedCrossRef

15.

Sablé-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. 2005;143(9):632–8.PubMedCrossRef

16.

Mahr A, Moosig F, Neumann T, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management. Curr Opin Rheumatol. 2014;26(1):16–23. doi:10.1097/BOR.0000000000000015.PubMedCrossRef

17.

Samson M, Puéchal X, Devilliers H, et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun. 2013;43:60–9. doi:10.1016/j.jaut.2013.03.003.PubMedCrossRef

18.

Nishino H, Rubino FA, DeRemee RA, Swanson JW, Parisi JE. Neurological involvement in Wegener‘s granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol. 1993;33(1):4–9. doi:10.1002/ana.410330103.PubMedCrossRef

19.

Stone JH. Limited versus severe Wegener’s granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum. 2003;48(8):2299–309. doi:10.1002/art.11075.PubMedCrossRef

20.

Miloslavsky EM, Specks U, Merkel PA, et al. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2013;65(9):2441–9. doi:10.1002/art.38044.PubMedCrossRef

21.

Godman GC, Churg J. Wegener’s granulomatosis: pathology and review of the literature. AMA Arch Pathol. 1954;58(6):533–53.PubMed

22.

Collins MP, Periquet MI. Prevalence of vasculitic neuropathy in Wegener granulomatosis. Arch Neurol. 2002;59(8):1333–4. author reply 1334.PubMedCrossRef

23.

De Groot K, Schmidt DK, Arlt AC, Gross WL, Reinhold-Keller E. Standardized neurologic evaluations of 128 patients with Wegener granulomatosis. Arch Neurol. 2001;58(8):1215–21.PubMedCrossRef

24.

Guillevin L, Le Thi Huong D u, Godeau P, Jais P, Wechsler B. Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis: a study in 165 patients. Br J Rheumatol. 1988;27(4):258–64.PubMedCrossRef

25.

Travers RL, Allison DJ, Brettle RP, Hughes GR. Polyarteritis nodosa: a clinical and angiographic analysis of 17 cases. Semin Arthritis Rheum. 1979;8(3):184–99.PubMedCrossRef

26.

Pagnoux C, Seror R, Henegar C, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum. 2010;62(2):616–26. doi:10.1002/art.27240.PubMedCrossRef

27.

Caselli RJ, Daube JR, Hunder GG, Whisnant JP. Peripheral neuropathic syndromes in giant cell (temporal) arteritis. Neurology. 1988;38(5):685–9.PubMedCrossRef

28.

Turesson C, Matteson EL. Vasculitis in rheumatoid arthritis. Curr Opin Rheumatol. 2009;21(1):35–40. doi:10.1097/BOR.0b013e32831c5303.PubMedCrossRef

29.

Makol A, Crowson CS, Wetter DA, Sokumbi O, Matteson EL, Warrington KJ. Vasculitis associated with rheumatoid arthritis: a case–control study. Rheumatology. 2014;53(5):890–9. doi:10.1093/rheumatology/ket475.PubMedCentralPubMedCrossRef

30.

Erhardt CC, Mumford PA, Venables PJ, Maini RN. Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis. 1989;48(1):7–13.PubMedCentralPubMedCrossRef

31.

Mellgren SI, Conn DL, Stevens JC, Dyck PJ. Peripheral neuropathy in primary Sjögren’s syndrome. Neurology. 1989;39(3):390–4.PubMedCrossRef

32.

Pavlakis PP, Alexopoulos H, Kosmidis ML, et al. Peripheral neuropathies in Sjögren’s syndrome: a critical update on clinical features and pathogenetic mechanisms. J Autoimmun. 2012;39(1–2):27–33. doi:10.1016/j.jaut.2012.01.003.PubMedCrossRef

33.

Govoni M, Bajocchi G, Rizzo N, et al. Neurological involvement in primary Sjögren’s syndrome: clinical and instrumental evaluation in a cohort of Italian patients. Clin Rheumatol. 1999;18(4):299–303.PubMedCrossRef

34.

Jamilloux Y, Magy L, Hurtevent J-F, et al. Immunological profiles determine neurological involvement in Sjögren’s syndrome. Eur J Intern Med. 2014;25(2):177–81. doi:10.1016/j.ejim.2013.10.005.PubMedCrossRef

35.

Wernicke D, Hess H, Gromnica-Ihle E, Krause A, Schmidt WA. Ultrasonography of salivary glands—a highly specific imaging procedure for diagnosis of Sjögren’s syndrome. J Rheumatol. 2008;35(2):285–93.PubMed

36.

Theander E, Mandl T. Primary Sjögren’s syndrome: diagnostic and prognostic value of salivary gland ultrasonography using a simplified scoring system. Arthrit Care Res (Hoboken). 2014;66(7):1102–7. doi:10.1002/acr.22264.CrossRef

37.

Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36–44. doi:10.1056/NEJMoa020286.PubMedCrossRef

38.

Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener’s granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol. 1998;9(5):842–52.PubMed

39.

Hamour S, Salama AD, Pusey CD. Management of ANCA-associated vasculitis: current trends and future prospects. Ther Clin Risk Manag. 2010;6:253–64.PubMedCentralPubMed

40.

Guillevin L, Lhote F, Jarrousse B, Fain O. Treatment of polyarteritis nodosa and Churg-Strauss syndrome. a meta-analysis of 3 prospective controlled trials including 182 patients over 12 years. Ann Med Interne (Paris). 1992;143(6):405–16.

41.

Samson M, Puéchal X, Devilliers H, et al. Mononeuritis multiplex predicts the need for immunosuppressive or immunomodulatory drugs for EGPA, PAN and MPA patients without poor-prognosis factors. Autoimmun Rev. 2014;13(9):945–53. doi:10.1016/j.autrev.2014.08.002.PubMedCrossRef

42.

Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum. 1997;40(12):2187–98. doi:10.1002/1529-0131(199712)40:12<2187::AID-ART12>3.0.CO;2-H.PubMedCrossRef

43.

Adu D, Pall A, Luqmani RA, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM. 1997;90(6):401–9.PubMedCrossRef

44.

Gayraud M, Guillevin L, Cohen P, et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol. 1997;36(12):1290–7.PubMedCrossRef

45.

Haubitz M, Schellong S, Göbel U, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum. 1998;41(10):1835–44. doi:10.1002/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q.PubMedCrossRef

46.

De Groot K, Harper L, Jayne DRW, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150(10):670–80.PubMedCrossRef

47.

Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis. 2012;71(6):955–60. doi:10.1136/annrheumdis-2011-200477.PubMedCrossRef

48.

Faurschou M, Sorensen IJ, Mellemkjaer L, et al. Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol. 2008;35(1):100–5.PubMed

49.

Mahr A, Heijl C, Le Guenno G, Faurschou M. ANCA-associated vasculitis and malignancy: current evidence for cause and consequence relationships. Best Pract Res Clin Rheumatol. 2013;27(1):45–56. doi:10.1016/j.berh.2012.12.003.PubMedCrossRef

50.

Le Guenno G, Mahr A, Pagnoux C, Dhote R, Guillevin L. Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. Arthritis Rheum. 2011;63(5):1435–45. doi:10.1002/art.30296.PubMedCrossRef

51.

Gorson KC. Therapy for vasculitic neuropathies. Curr Treat Options Neurol. 2006;8(2):105–17.PubMedCrossRef

52.

Wall N, Harper L. Complications of long-term therapy for ANCA-associated systemic vasculitis. Nat Rev Nephrol. 2012;8(9):523–32. doi:10.1038/nrneph.2012.107.PubMedCrossRef

53.

Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68(3):310–7. doi:10.1136/ard.2008.088096.PubMedCrossRef

54.

Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369(5):417–27. doi:10.1056/NEJMoa1213277.PubMedCrossRef

55.

Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771–80. doi:10.1056/NEJMoa1404231.PubMedCrossRef

56.

Miloslavsky EM, Specks U, Merkel PA. Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol (Hoboken, NJ). 2014;66(11):3151–9. doi:10.1002/art.38788.CrossRef

57.

Thiel J, Hässler F, Salzer U, Voll RE, Venhoff N. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Arthritis Res Ther. 2013;15(5):R133. doi:10.1186/ar4313.PubMedCentralPubMedCrossRef

58.

Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2009;60(7):2156–68. doi:10.1002/art.24637.PubMedCrossRef

59.

Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): ten-year experience at a single center. Arthritis Rheum. 2012;64(11):3770–8. doi:10.1002/art.34584.PubMedCrossRef

60.

Puéchal X, Gottenberg JE, Berthelot JM, et al. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: results from the AutoImmunity and Rituximab Registry. Arthrit Care Res (Hoboken). 2012;64(3):331–9. doi:10.1002/acr.20689.CrossRef

61.

Kissel JT, Levy RJ, Mendell JR, Griggs RC. Azathioprine toxicity in neuromuscular disease. Neurology. 1986;36(1):35–9.PubMedCrossRef

62.

De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52(8):2461–9. doi:10.1002/art.21142.PubMedCrossRef

63.

Jayne DR, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM. 2000;93(7):433–9.PubMedCrossRef

64.

Levy Y, Uziel Y, Zandman G, et al. Response of vasculitic peripheral neuropathy to intravenous immunoglobulin. Ann N Y Acad Sci. 2005;1051:779–86. doi:10.1196/annals.1361.121.PubMedCrossRef

65.

Tsurikisawa N, Taniguchi M, Saito H, et al. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol. 2004;92(1):80–7. doi:10.1016/S1081-1206(10)61714-0.PubMedCrossRef

66.

Martinez V, Cohen P, Pagnoux C, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 2008;58(1):308–17. doi:10.1002/art.23147.PubMedCrossRef

67.

Matsuda T, Arimura Y, Yoshihara K, Komagata Y, Kaname S, Yamada A. Efficacy of high-dose intravenous immunoglobulin therapy for peripheral neuropathy in the remission stage of eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss syndrome). Nihon Rinsho Meneki Gakkai Kaishi. 2013;36(4):217–25.PubMedCrossRef

68.

Koike H, Akiyama K, Saito T, Sobue G. Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): a multicenter, double-blind trial. J Neurol. 2015;262(3):752–9. doi:10.1007/s00415-014-7618-y.PubMedCentralPubMedCrossRef

69.

Walsh M, Casian A, Flossmann O, et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int. 2013;84(2):397–402. doi:10.1038/ki.2013.131.PubMedCrossRef

70.

Guillevin L, Fain O, Lhote F, et al. Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients. Arthritis Rheum. 1992;35(2):208–15.PubMedCrossRef

71.

Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010;304(21):2381–8. doi:10.1001/jama.2010.1658.PubMedCrossRef

72.

Metzler C, Miehle N, Manger K, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener’s granulomatosis. Rheumatology (Oxford). 2007;46(7):1087–91. doi:10.1093/rheumatology/kem029.CrossRef

73.

Metzler C, Schnabel A, Gross WL, Hellmich B. A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome. Clin Exp Rheumatol. 2008;26(3 Suppl 49):S35–40.PubMed

74.

Moosig F, Gross WL, Herrmann K, Bremer JP, Hellmich B. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med. 2011;155(5):341–3. doi:10.7326/0003-4819-155-5-201109060-00026.PubMedCrossRef

75.

Guillevin L, Pagnoux C. Therapeutic strategies for systemic necrotizing vasculitides. Allergol Int. 2007;56(2):105–11. doi:10.2332/allergolint.R-07-144.PubMedCrossRef

76.

Mazzaro C, Zorat F, Caizzi M, et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol. 2005;42(5):632–8. doi:10.1016/j.jhep.2004.10.031.PubMedCrossRef

77.

Saadoun D, Resche-Rigon M, Thibault V, Piette J-C, Cacoub P. Antiviral therapy for hepatitis C virus—associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum. 2006;54(11):3696–706. doi:10.1002/art.22168.PubMedCrossRef

78.

Saadoun D, Resche Rigon M, Thibault V, et al. Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis. 2014;73(5):831–7. doi:10.1136/annrheumdis-2012-202770.PubMedCentralPubMedCrossRef

79.

Saadoun D, Resche Rigon M, Pol S, et al. PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. J Hepatol. 2015;62(1):24–30. doi:10.1016/j.jhep.2014.08.015.PubMedCrossRef

80.•

Cacoub P, Terrier B, Saadoun D. Hepatitis C virus-induced vasculitis: therapeutic options. Ann Rheum Dis. 2014;73(1):24–30. doi:10.1136/annrheumdis-2013-203883. It is an overview of the treatment options for infectious large arteriole vasculitis caused by hepatitis C virus.PubMedCrossRef

81.

Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010;116(3):326–34. doi:10.1182/blood-2009-10-248518. quiz 504–505.PubMedCrossRef

82.

Saadoun D, Resche-Rigon M, Sene D, Perard L, Karras A, Cacoub P. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis. 2008;67(10):1431–6. doi:10.1136/ard.2007.081653.PubMedCrossRef

83.

Ramos-Casals M, Stone JH, Cid MC, Bosch X. The cryoglobulinaemias. Lancet. 2012;379(9813):348–60. doi:10.1016/S0140-6736(11)60242-0.PubMedCrossRef

84.

Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011;365(22):2067–77. doi:10.1056/NEJMoa1105143.PubMedCrossRef

85.

Guillevin L, Mahr A, Callard P, et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore). 2005;84(5):313–22.CrossRef

86.

Dyck PJ, Benstead TJ, Conn DL, Stevens JC, Windebank AJ, Low PA. Nonsystemic vasculitic neuropathy. Brain. 1987;110(Pt 4):843–53.PubMedCrossRef

87.

Davies L, Spies JM, Pollard JD, McLeod JG. Vasculitis confined to peripheral nerves. Brain. 1996;119(Pt 5):1441–8.PubMedCrossRef

88.

Sugiura M, Koike H, Iijima M, et al. Clinicopathologic features of nonsystemic vasculitic neuropathy and microscopic polyangiitis-associated neuropathy: a comparative study. J Neurol Sci. 2006;241(1–2):31–7. doi:10.1016/j.jns.2005.10.018.PubMedCrossRef

89.

Dyck PJ, Norell JE. Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy. Neurology. 1999;53(9):2113–21.PubMedCrossRef

90.

Dyck PJB, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve. 2002;25(4):477–91.PubMedCrossRef

91.

Massie R, Mauermann ML, Staff NP, et al. Diabetic cervical radiculoplexus neuropathy: a distinct syndrome expanding the spectrum of diabetic radiculoplexus neuropathies. Brain. 2012;135(Pt 10):3074–88. doi:10.1093/brain/aws244.PubMedCrossRef

92.

Dyck PJ, Engelstad J, Norell J. Microvasculitis in non-diabetic lumbosacral radiculoplexus neuropathy (LSRPN): similarity to the diabetic variety (DLSRPN). J Neuropathol Exp Neurol. 2000;59(6):525–38.PubMed

93.

Evans BA, Stevens JC, Dyck PJ. Lumbosacral plexus neuropathy. Neurology. 1981;31(10):1327–30.PubMedCrossRef

94.

Sander JE, Sharp FR. Lumbosacral plexus neuritis. Neurology. 1981;31(4):470–3.PubMedCrossRef

95.

Dyck PJ, Norell JE. Non-diabetic lumbosacral radiculoplexus neuropathy: natural history, outcome and comparison with the diabetic variety. Brain. 2001;124(Pt 6):1197–207.PubMedCrossRef

96.

Garces-Sanchez M, Laughlin RS, Dyck PJ, Engelstad JK, Norell JE, Dyck PJB. Painless diabetic motor neuropathy: a variant of diabetic lumbosacral radiculoplexus neuropathy? Ann Neurol. 2011;69(6):1043–54. doi:10.1002/ana.22334.PubMedCentralPubMedCrossRef

97.

Collins MP, Dyck PJB, Gronseth GS, et al. Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Peripher Nerv Syst. 2010;15(3):176–84. doi:10.1111/j.1529-8027.2010.00281.x.PubMedCrossRef

98.

Thaisetthawatkul P, Dyck PJB. Treatment of diabetic and nondiabetic lumbosacral radiculoplexus neuropathy. Curr Treat Options Neurol. 2010;12(2):95–9. doi:10.1007/s11940-010-0059-8.PubMedCrossRef

99.

Dyck PJB, O’brien PBP. The multi-center double-blind controlled trial of IV methylprednisolone in diabetic lumbosacral radiculoplexus neuropathy. Neurology. 2006;66 suppl 2:A191.

100.

Said G, Goulon-Goeau C, Lacroix C, Moulonguet A. Nerve biopsy findings in different patterns of proximal diabetic neuropathy. Ann Neurol. 1994;35(5):559–69. doi:10.1002/ana.410350509.PubMedCrossRef

101.

Krendel DA, Costigan DA, Hopkins LC. Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol. 1995;52(11):1053–61.PubMedCrossRef

102.

Pascoe MK, Low PA, Windebank AJ, Litchy WJ. Subacute diabetic proximal neuropathy. Mayo Clin Proc. 1997;72(12):1123–32. doi:10.1016/S0025-6196(11)63674-4.PubMedCrossRef

103.

Kilfoyle D, Kelkar P, Parry GJ. Pulsed methylprednisolone is a safe and effective treatment for diabetic amyotrophy. J Clin Neuromuscul Dis. 2003;4(4):168–70.PubMedCrossRef

104.

Dyck PJ, Norell JE. Methylprednisolone may improve lumbosacral radiculoplexus neuropathy. Can J Neurol Sci. 2001;28(3):224–7.PubMedCrossRef

105.

Bradley WG, Chad D, Verghese JP, et al. Painful lumbosacral plexopathy with elevated erythrocyte sedimentation rate: a treatable inflammatory syndrome. Ann Neurol. 1984;15(5):457–64. doi:10.1002/ana.410150510.PubMedCrossRef

106.

Tamburin S, Zanette G. Intravenous immunoglobulin for the treatment of diabetic lumbosacral radiculoplexus neuropathy. Pain Med. 2009;10(8):1476–80. doi:10.1111/j.1526-4637.2009.00704.x.PubMedCrossRef

Titel: Vasculitic Neuropathies
verfasst von: Elie Naddaf, MD
P. James Bonham Dyck, MD
Publikationsdatum: 01.10.2015
Verlag: Springer US
Erschienen in: Current Treatment Options in Neurology / Ausgabe 10/2015
Print ISSN: 1092-8480
Elektronische ISSN: 1534-3138
DOI: https://doi.org/10.1007/s11940-015-0374-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen